ERBB2 and breast carcinoma: In recent years, there have been major improvements in the treatment of both human epidermal growth factor receptor 2 (HER2)-negative molecular subtypes of breast cancer (i.e., triple negative breast cancer (TNBC) and hormone receptor-positive, HER2-negative (HRpos/HER2neg) breast cancer).